HDAC Screening identifies the HDAC Class I Inhibitor Romidepsin as a promising Epigenetic Drug for Biliary Tract Cancer

Christian Mayr; Tobias Kiesslich; Sara Erber; Dino Bekric; Heidemarie Dobias; Marlena Beyreis; Markus Ritter; Tarkan Jager; Bettina Neumayer; Paul Winkelmann; Eckhard Klieser; Daniel Neureiter

doi:10.1096/fasebj.2021.35.S1.05128

HDAC Screening identifies the HDAC Class I Inhibitor Romidepsin as a promising Epigenetic Drug for Biliary Tract Cancer

Christian Mayr, Tobias Kiesslich, Sara Erber, Dino Bekric, Heidemarie Dobias, Marlena Beyreis, Markus Ritter, Tarkan Jager, Bettina Neumayer, Paul Winkelmann, Eckhard Klieser, Daniel Neureiter

Research output: Contribution to journal › Abstract (Journal) › peer-review

8 Citations (Web of Science)

Original language	English
Number of pages	2
Journal	FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
DOIs	https://doi.org/10.1096/fasebj.2021.35.S1.05128
Publication status	Published - May 2021
Event	Experimental Biology Meeting - Duration: 27 Apr 2021 → 30 Apr 2021

Access to Document

10.1096/fasebj.2021.35.S1.05128

Cite this

Mayr, C., Kiesslich, T., Erber, S., Bekric, D., Dobias, H., Beyreis, M., Ritter, M., Jager, T., Neumayer, B., Winkelmann, P., Klieser, E., & Neureiter, D. (2021). HDAC Screening identifies the HDAC Class I Inhibitor Romidepsin as a promising Epigenetic Drug for Biliary Tract Cancer. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. https://doi.org/10.1096/fasebj.2021.35.S1.05128

@article{16f2ed8f8a804c3a9feb0019c3eccec8,

title = "HDAC Screening identifies the HDAC Class I Inhibitor Romidepsin as a promising Epigenetic Drug for Biliary Tract Cancer",

author = "Christian Mayr and Tobias Kiesslich and Sara Erber and Dino Bekric and Heidemarie Dobias and Marlena Beyreis and Markus Ritter and Tarkan Jager and Bettina Neumayer and Paul Winkelmann and Eckhard Klieser and Daniel Neureiter",

year = "2021",

month = may,

doi = "10.1096/fasebj.2021.35.S1.05128",

language = "English",

journal = " FASEB journal : official publication of the Federation of American Societies for Experimental Biology.",

issn = "0892-6638",

publisher = "Wiley Verlag ",

note = "Experimental Biology Meeting ; Conference date: 27-04-2021 Through 30-04-2021",

}

Mayr, C , Kiesslich, T, Erber, S, Bekric, D , Dobias, H, Beyreis, M, Ritter, M, Jager, T, Neumayer, B, Winkelmann, P, Klieser, E & Neureiter, D 2021, 'HDAC Screening identifies the HDAC Class I Inhibitor Romidepsin as a promising Epigenetic Drug for Biliary Tract Cancer', FASEB journal : official publication of the Federation of American Societies for Experimental Biology. https://doi.org/10.1096/fasebj.2021.35.S1.05128

HDAC Screening identifies the HDAC Class I Inhibitor Romidepsin as a promising Epigenetic Drug for Biliary Tract Cancer. / Mayr, Christian ; Kiesslich, Tobias; Erber, Sara et al.
In: FASEB journal : official publication of the Federation of American Societies for Experimental Biology., 05.2021.

Research output: Contribution to journal › Abstract (Journal) › peer-review

TY - JOUR

T1 - HDAC Screening identifies the HDAC Class I Inhibitor Romidepsin as a promising Epigenetic Drug for Biliary Tract Cancer

AU - Mayr, Christian

AU - Kiesslich, Tobias

AU - Erber, Sara

AU - Bekric, Dino

AU - Dobias, Heidemarie

AU - Beyreis, Marlena

AU - Ritter, Markus

AU - Jager, Tarkan

AU - Neumayer, Bettina

AU - Winkelmann, Paul

AU - Klieser, Eckhard

AU - Neureiter, Daniel

PY - 2021/5

Y1 - 2021/5

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=pmu_pure&SrcAuth=WosAPI&KeyUT=WOS:000669893105308&DestLinkType=FullRecord&DestApp=WOS

U2 - 10.1096/fasebj.2021.35.S1.05128

DO - 10.1096/fasebj.2021.35.S1.05128

M3 - Abstract (Journal)

SN - 0892-6638

JO - FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

JF - FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

T2 - Experimental Biology Meeting

Y2 - 27 April 2021 through 30 April 2021

ER -

HDAC Screening identifies the HDAC Class I Inhibitor Romidepsin as a promising Epigenetic Drug for Biliary Tract Cancer

Access to Document

Other files and links

Cite this